HistoGeneX is now CellCarta Learn More

Martin LeBlanc

Martin LeBlanc Chief Executive Officer LI In Bug 300x255

Martin LeBlanc Headshot

A co-founder of Caprion, Martin has for over 15 years led Caprion’s technology development, laboratory operations and commercial strategy focused on specialized laboratory research services in the fields of proteomics, immune monitoring, and personalized medicine. Profitable and rapidly growing based on its research contracts and strategic partnerships with over 75 global pharmaceutical and biotechnology companies, Caprion is also developing its own proprietary diagnostics tests for cancer, diabetes, and infectious diseases. Since 2007, Martin has concluded 3 company acquisitions and has successively managed Caprion under the ownership of 3 leading healthcare private equity firms, including the recent sale of Caprion to GHO Capital in July 2017.

Prior to Caprion, Martin began his professional career as a management consultant with McKinsey & Company. He then initiated his career as a biotech entrepreneur at Advanced Bioconcept, initially as Vice-President of Sales & Marketing and then as General Manager following the company’s acquisition by NEN Life Sciences (now part of Perkin-Elmer). Martin is currently a member of the Board of Directors of Caprion, Softbox Systems, Mispro Biotech Services, Prevtec Microbia, Montreal InVivo, the Atlantic Cancer Research Institute and of the Centre for Commercialization of Cancer Immunotherapy. He is also a member of the Investment Committee of the Amorchem venture fund.

Martin earned his bachelor’s degree in Economics from the University of Moncton prior to completing an M.A. in Economics and Politics at Oxford University as a Rhodes Scholar.